Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,789 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Sham Treatment Clear all

Conditions: Cardiovascular Disease
Interventions: Antioxidant cocktail, Biopsy, Placebo, NMD; 0.4mg sub-lingual nitroglycerin spray; Dietary Supplement · Other · Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Stroke
Interventions: tRNS (Transcranial Random Noise Stimulation), FES (Functional Electrical Stimulation)-assisted task-specific practice, Sham-tRNS (Transcranial Random Noise Stimulation); Device
Lead sponsor: University of Utah; Other
Eligibility: 40 Years to 85 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: X Linked Myotubular Myopathy
Interventions: ApoTamox 10mg, Placebo; Drug
Lead sponsor: James Dowling; Other
Eligibility: 6 Months and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois • Rockville, Maryland

Conditions: Rectal Microbicides
Interventions: Tenofovir 1% gel, 2% N-9 gel, HEC Placebo gel; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Fluid Retention, Sodium Retention, Heat Stress, Dehydration (Physiology), Renal Injury, Electrolyte and Fluid Balance Conditions
Interventions: PR Lotion - AMP Human Performance, Placebo Lotion, AminoVital - Rapid Recovery, Placebo Supplement; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Trigeminal Neuralgia
Interventions: lamotrigine, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 15 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Urinary Tract Infection, Recurrent
Interventions: phage therapy, control; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Degenerative Disc Disease
Interventions: Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP), Sham procedure; Biological · Other
Lead sponsor: Regenexx, LLC; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Broomfield, Colorado • Lone Tree, Colorado

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Blood Draw, CSF collection by lumbar puncture (Optional); Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 13
States / cities: Berkeley, California • Los Angeles, California • Sacramento, California + 10 more

Conditions: Obesity, Postmenopausal Women
Interventions: placebo softgel, DeltaGold® Tocotrienol 70%; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features, Bipolar Disorder With Psychotic Features, Psychosis NOS, Schizophreniform Disorder, Psychotic Disorder, Cognition
Interventions: Modafinil, D-serine solution, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 35 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: COPD
Interventions: Placebo; Drug
Lead sponsor: Gelb, Arthur F., M.D.; Individual
Eligibility: 40 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Lakewood, California

Conditions: Knee Pain Chronic
Interventions: transcranial direct current stimulation, physical therapy; Device · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer's Disease
Interventions: S -Equol, Placebo; Drug
Lead sponsor: Russell Swerdlow, MD; Other
Eligibility: 60 Years to 90 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Pain, Anxiety, Nausea
Interventions: Midazolam, Ibuprofen, Placebo-Cherry syrup, Lidocaine; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hypertension, Stress, Psychological, Blood Pressure
Interventions: Prazosin, Placebo; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Feeding Behavior, Feeding Disorder of Infancy or Early Childhood
Interventions: Megestrol Acetate, iKanEat Behavioral Intervention; Drug · Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 9 Months to 108 Months
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 8
States / cities: San Diego, California • Orlando, Florida • Indianapolis, Indiana + 5 more

Conditions: Allergic Rhinitis
Interventions: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control; Biological · Other
Lead sponsor: Immunomic Therapeutics, Inc.; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Type 1 Diabetes
Interventions: Ramipril, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 13 Years to 50 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Gainesville, Florida • Chicago, Illinois • Maywood, Illinois

Conditions: Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions: Placebo, Vanquix Auto-Injector (Diazepam Injection); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 86
States / cities: Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more

Conditions: Supracondylar Humerus Fracture, Post Operative Wound Infection
Interventions: Cefazolin, Clindamycin, Saline; Drug
Lead sponsor: Sumit Gupta; Other
Eligibility: Up to 13 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Moderate to Severe Insomnia
Interventions: Transcranial alternating current stimulator; Device
Lead sponsor: Nexalin Technology; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: Curcumin (Longvida™); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Beverly Hills, California • Los Angeles, California

Conditions: Heart Failure
Interventions: Cognitive Behavioral Therapy, Attention Placebo; Behavioral
Lead sponsor: University of Kentucky; Other
Eligibility: 21 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)

A Novel Multimodal Approach to Promote Motor Recovery and Plasticity After Stroke

Tamoxifen Therapy for Myotubular Myopathy

Rectal Safety and Acceptability Study of Tenofovir 1% Gel

The Effect of AMP Human Sodium Bicarbonate Lotion on Dehydrated Heat Stress

Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia

Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients

Trial for Treating Painful Degenerative Disc Disease

Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

Tocotrienols for Obesity of Postmenopausal Women

Cognitive Strategies in Early Psychosis 2

Dynamic Hyperinflation and Tiotropium

Transcranial Direct Current Stimulation in Conjunction With Individualized Physical Therapy for Individuals With Chronic Knee Pain

S-Equol in Alzheimer's Disease (SEAD) Trial

Evaluation of Oral Midazolam in First-trimester Surgical Abortions

Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress

iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)

HALO Clarity™ Cranial Alternating Current Stimulation Therapy for Adults With Moderate-to-Severe Insomnia

Curcumin in Rheumatoid Arthritis

Impact of a Psychological Biofeedback-Relaxation Intervention on Clinical, Physical and Psychological Outcomes in Patients With Heart Failure